ADAR1 as a Therapeutic Target in Type I Interferon Signaling-High Cancer

Time: 2:20 pm
day: Day Two


• A subset of cancer cell lines and tumors displays endogenous elevated Type I IFN signaling
• ADAR1 loss induces selective cell killing in these cells through elevated dsRNA signaling by MDA5 (with downstream IFN production) and PKR (and downstream inhibition of translation)
• These studies indicate an ADAR1 inhibitor would be a useful therapeutic for cancer with elevated Type I IFN signaling and possibly in combination with existing immunotherapies